197 related articles for article (PubMed ID: 36310301)
1. Prognostic relevance of mixed histological subtypes in invasive breast carcinoma: a retrospective analysis.
Rechsteiner A; Dietrich D; Varga Z
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4967-4978. PubMed ID: 36310301
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type.
Kim J; Kim JY; Lee HB; Lee YJ; Seong MK; Paik N; Park WC; Park S; Jung SP; Bae SY;
Breast Cancer Res Treat; 2020 Nov; 184(2):527-542. PubMed ID: 32794061
[TBL] [Abstract][Full Text] [Related]
3. The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.
Hu J; Lang R; Zhao W; Jia Y; Tong Z; Shi Y
Breast Cancer Res Treat; 2023 Jul; 200(1):23-36. PubMed ID: 37160814
[TBL] [Abstract][Full Text] [Related]
4. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
[TBL] [Abstract][Full Text] [Related]
5. Refinement of breast cancer classification by molecular characterization of histological special types.
Weigelt B; Horlings HM; Kreike B; Hayes MM; Hauptmann M; Wessels LF; de Jong D; Van de Vijver MJ; Van't Veer LJ; Peterse JL
J Pathol; 2008 Oct; 216(2):141-50. PubMed ID: 18720457
[TBL] [Abstract][Full Text] [Related]
6. Expression of calretinin in high-grade hormone receptor-negative invasive breast carcinomas: correlation with histological and molecular subtypes.
Micello D; Bossi A; Marando A; Dainese E; Sessa F; Capella C
Virchows Arch; 2017 Jul; 471(1):13-21. PubMed ID: 28550498
[TBL] [Abstract][Full Text] [Related]
7. The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer.
Liao HY; Zhang WW; Sun JY; Li FY; He ZY; Wu SG
J Cancer; 2018; 9(2):296-303. PubMed ID: 29344276
[No Abstract] [Full Text] [Related]
8. Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis.
Han Y; Wang J; Xu B
Breast; 2020 Dec; 54():114-120. PubMed ID: 32979771
[TBL] [Abstract][Full Text] [Related]
9. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
Mercogliano MF; Inurrigarro G; De Martino M; Venturutti L; Rivas MA; Cordo-Russo R; Proietti CJ; Fernández EA; Frahm I; Barchuk S; Allemand DH; Figurelli S; Deza EG; Ares S; Gercovich FG; Cortese E; Amasino M; Guzmán P; Roa JC; Elizalde PV; Schillaci R
BMC Cancer; 2017 Dec; 17(1):895. PubMed ID: 29281999
[TBL] [Abstract][Full Text] [Related]
10. The 21-Gene Recurrence Score in Special Histologic Subtypes of Breast Cancer.
Gulbahce HE; Downs-Kelly E; Herget KA; Stoddard GJ
Arch Pathol Lab Med; 2022 Apr; 146(4):478-484. PubMed ID: 34343231
[TBL] [Abstract][Full Text] [Related]
11. Ductal carcinoma in situ (DCIS) in the male breast: a morphologic study of 84 cases of pure DCIS and 30 cases of DCIS associated with invasive carcinoma--a preliminary report.
Hittmair AP; Lininger RA; Tavassoli FA
Cancer; 1998 Nov; 83(10):2139-49. PubMed ID: 9827718
[TBL] [Abstract][Full Text] [Related]
12. Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma.
Pereira H; Pinder SE; Sibbering DM; Galea MH; Elston CW; Blamey RW; Robertson JF; Ellis IO
Histopathology; 1995 Sep; 27(3):219-26. PubMed ID: 8522285
[TBL] [Abstract][Full Text] [Related]
13. Disease Behavior and Treatment Response of Special Histological Types of Triple-Negative Breast Cancer.
Bonadio RC; Costa FA; Mendes SV; Araujo BJ; Nader-Marta G; Pinto PBC; Batista DN; Testa L; Ferrari MS
Clin Breast Cancer; 2022 Dec; 22(8):e892-e900. PubMed ID: 36130851
[TBL] [Abstract][Full Text] [Related]
14. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.
Nagao T; Kinoshita T; Hojo T; Tsuda H; Tamura K; Fujiwara Y
Breast; 2012 Jun; 21(3):289-95. PubMed ID: 22277312
[TBL] [Abstract][Full Text] [Related]
15. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.
Dieci MV; Orvieto E; Dominici M; Conte P; Guarneri V
Oncologist; 2014 Aug; 19(8):805-13. PubMed ID: 24969162
[TBL] [Abstract][Full Text] [Related]
16. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up.
Ellis IO; Galea M; Broughton N; Locker A; Blamey RW; Elston CW
Histopathology; 1992 Jun; 20(6):479-89. PubMed ID: 1607149
[TBL] [Abstract][Full Text] [Related]
17. Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer.
Cosar R; Sut N; Topaloglu S; Tastekin E; Nurlu D; Ozler T; Şenödeyici E; Dedeli M; Chousein M; Cicin I
PLoS One; 2023; 18(7):e0283445. PubMed ID: 37428725
[TBL] [Abstract][Full Text] [Related]
18. WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes.
Domfeh AB; Carley AL; Striebel JM; Karabakhtsian RG; Florea AV; McManus K; Beriwal S; Bhargava R
Mod Pathol; 2008 Oct; 21(10):1217-23. PubMed ID: 18469795
[TBL] [Abstract][Full Text] [Related]
19. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.
Droeser R; Zlobec I; Kilic E; Güth U; Heberer M; Spagnoli G; Oertli D; Tapia C
BMC Cancer; 2012 Apr; 12():134. PubMed ID: 22471961
[TBL] [Abstract][Full Text] [Related]
20. 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.
Celis JE; Gromov P; Cabezón T; Moreira JM; Friis E; Jirström K; Llombart-Bosch A; Timmermans-Wielenga V; Rank F; Gromova I
Mol Cell Proteomics; 2008 Oct; 7(10):1795-809. PubMed ID: 18632593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
